[{"id":"632e086b-4980-45e3-a3e6-bddfd082cd93","acronym":"","url":"https://clinicaltrials.gov/study/NCT05744687","created_at":"2023-02-27T15:00:55.877Z","updated_at":"2024-07-02T16:35:00.952Z","phase":"Phase 2/3","brief_title":"Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer","source_id_and_acronym":"NCT05744687","lead_sponsor":"Shanghai Pharmaceuticals Holding Co., Ltd","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive • HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e letrozole • SPH4336"],"overall_status":"Recruiting","enrollment":" Enrollment 374","initiation":"Initiation: 04/24/2023","start_date":" 04/24/2023","primary_txt":" Primary completion: 08/18/2024","primary_completion_date":" 08/18/2024","study_txt":" Completion: 12/16/2024","study_completion_date":" 12/16/2024","last_update_posted":"2024-05-24"}]